Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HRS-1780 in Renal Impairment
NCT06039254Phase 1Unknown
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Sep 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of HRS-1780 in chronic kidney disease (CKD) (3 arms), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Maximum Plasma Concentration at 1 week, Area Under the Curve to Last Quantifiable Concentration at 1 week and 1 more. Status: unknown.
02
Drugs
HRS-1780
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06039254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06039254.